PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33732370-4	2021	To block the PDGF-BB signaling pathway, PDGFR inhibitors (sunitinib or ponatinib) were employed.	ponatinib	71-80	platelet derived growth factor receptor beta	Homo sapiens	40-45	
33732370-9	2021	Therefore, it is proposed that PDGFR inhibitors, including sunitinib and ponatinib, should be applied effectively to treat ER-alpha+ breast cancer.	ponatinib	73-82	platelet derived growth factor receptor beta	Homo sapiens	31-36	
30705592-4	2019	Due to ponatinib"s unique multi-targeted characteristics, further studies have demonstrated its ability to target other important tyrosine kinases (FGFR, PDGFR, SRC, RET, KIT, and FLT1) in other human malignancies.	ponatinib	7-16	platelet derived growth factor receptor beta	Homo sapiens	154-159	
24407160-14	2014	Although several different PDGFR-targeting agents are effective, the most potent drug appears to be ponatinib.	ponatinib	100-109	platelet derived growth factor receptor beta	Homo sapiens	27-32